Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756457 | 0.92 | MEN1 (0.47) | SPHK1TSHRTP53EPHX1EPHX2 | |
| SCHEMBL9304492 | 0.92 | TSHR (0.54) | SPHK1TSHRTP53EPHX1EPHX2 | |
| SCHEMBL69703 | 0.89 | PTPN1 (0.53) | SPHK1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL138295 | 0.85 | MEN1 (0.51) | SPHK1TSHRTP53EPHX1EPHX2 | |
| SCHEMBL307975 | 0.85 | SPHK1 (0.55) | SPHK1TSHRTP53EPHX1EPHX2 | |
| SCHEMBL14817483 | 0.85 | NAPRT (0.53) | SPHK1TSHRTP53EPHX1EPHX2 | |
| SCHEMBL24444376 | 0.83 | SPHK1 (0.43) | SPHK1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL105644 | 0.83 | ALDH1A1 (0.48) | FAAHALDH1A1HDAC1 | |
| SCHEMBL22453144 | 0.83 | MAOA (0.50) | EPHX1MEN1KMT2AFAAHLMNA | |
| SCHEMBL10202156 | 0.83 | TSHR (0.48) | SPHK1TSHRTP53EPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105924403-B | A kind of ring propane diamide compound with anti-tumor activity and its preparation method and application | 西安交通大学 | 2018-07-17 | — | — | CN | claimed |
| CN-105924403-A | Cyclomalonamide compound with antitumor activity, and preparation method and application thereof | 西安交通大学 | 2016-09-07 | — | — | CN | claimed |
| CN-105906568-A | Cyclopropane diamide compound with antitumor activity and preparation method and application thereof | 西安交通大学 | 2016-08-31 | — | — | CN | claimed |
| JP-57002272-A | — | — | None | — | — | JP | disclosed |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220175757-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2022-06-09 | — | — | US | disclosed |
| CN-109879827-B | Indazole derivative and application thereof | 陕西理工大学 | 2022-05-31 | — | — | CN | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006014325-A2 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-5292937-A | Use of malonic acid derivative compounds for retarding plant growth | RHONE-POULENC INC. (US) | 1994-03-08 | — | — | US | disclosed |
| US-5123951-A | Ethylene response inducing agent and malonic acid derivative | RHONE-POULENC NEDERLAND B.V. (NL) | 1992-06-23 | — | — | US | disclosed |
| JP-S572272-A | PREPARATION OF N-PHENYLCYCLOPROPANEDICARBOXYLIC ACID IMIDE DERIVATIVE | SUMITOMO CHEM CO LTD | 1982-01-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150956-A1 | MYC INHIBITORS AND USES THEREOF | MYC, AURKA, AURKC | SPHK1 1668/4885TSHR 4277/4885TP53 11/4885 |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, MAP3K1 | SPHK1 1139/4885TSHR 1037/4885TP53 1018/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | SPHK1 1254/4885TSHR 396/4885TP53 246/4885 |
| US-20220175757-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SPHK1 3407/4885TSHR 2328/4885TP53 2633/4885 |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, PRKCH | SPHK1 1488/4885TSHR 997/4885TP53 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.